Acupuncture use was nearly six times more common among chiropractic users than in the overall population (2.2% vs. 0.37%); similarly, nearly half (42.5%) of acupuncture users also had a claim for chiropractic. Over one-in-five patients (21.0%) with general joint or back pain used chiropractic, of which 2.65% also used acupuncture. CONCLUSIONS: Despite trends suggesting increased use of chiropractic and acupuncture, their use remains very low in commercial health insurance plans, including patients with inflammation and pain-related conditions. While still very low, acupuncture use was more common among chiropractic users than in the overall population. 
OBJECTIVES:
The aim of this study was to evaluate the impact of race on quality of anticoagulation control in patients undergoing major orthopedic surgery.
METHODS:
We conducted a retrospective, observational cohort study in an inner-city underserved population treated with warfarin thromboprophylaxis after total hip replacement (THR) or total knee replacement (TKR), referred to a specialized antithrombosis clinic from 1998 to 2009. Significant variables from simple linear regression (p < 0.1) were entered in stepwise multivariate logistic regression (alpha < 0.05) to evaluate the effect of race on quality of anticoagulation control, defined as within-patient proportion of international normalized ratio (INR) levels spent in therapeutic range (INR of 2-3 ± 0.2). RESULTS: A total of 400 consecutive patients were evaluated. The average age was 58.4±12.5, 56% were African-American, and 26% were Hispanic. The average length of warfarin therapy was 50±21 days, and the average within-patient proportion of INR levels spent in therapeutic range was 39.2±20.5%. AfricanAmericans (β= -8.59, p < 0.0001) had lower within-patient proportion of INR levels spent in therapeutic range compared to non-African-Americans. In addition, males (β= -5.17, p = 0.0069), higher warfarin dose (β= -3.13, p <0.0001), higher frequency of anticoagulation monitoring visits (β= -1.13, p = 0.0214) and non-adherence with warfarin (β= -0.31, p <0.0001) were significantly associated with a lower proportion of INR levels in therapeutic range. After controlling for age, gender, comorbidities, and significant covariates, the effect of AfricanAmerican race remained significant (β= -6.90, p = 0.0001). CONCLUSIONS: In this inner-city underserved population treated with warfarin thromboprophylaxis for THR and TKR, African-Americans tended to have lower proportion of INR levels in therapeutic range than non-African-Americans. Studies are needed to further elucidate factors driving substandard anticoagulation control in minority patients. 
SYSTEMIC DISORDERS/CONDITIONS -Cost

OBJECTIVES:
Neuropathic pain (NeP) is a pain caused by a lesion or disease of the somatosensory nervous system (International Association for the Study of Pain -IASP 2011). In many cases NeP is secondary to herpes zoster infection and as a complication of diabetes mellitus. This study aimed to assess the budget impact of pregabalin in NeP in adult Colombian population. METHODS: A budget impact model was developed with a time horizon of 1 year from the social perspective (direct and indirect costs included). Cohort contains 155,030 patients over 18 years with NeP, according to Colombian prevalence and considers 20% of patients have access to medical treatment. Direct costs (drug acquisition, medical visits with general practitioners, specialists and emergency visits) and indirect costs (disability payments) of managing patients with neuropathic pain were estimated from Colombian sources (tariff manuals and pricing rulings). Comparators included those locally approved for NeP: pregabalin (150-300 mg/day) versus duloxetine (60 mg/day). Univariate deterministic and probabilistic sensitivity analyses were done. Costs are in 2012 US$. RESULTS: Assuming that each comparator had a 100% market share, the average total costs of treating NeP patients for 1 year, with the comparators were: pregabalin US $132,965,443 (51.7% drug acquisition, 26.4% medical visits and 21.9% indirect costs) and duloxetine US $220,883,844 (68.6% drug acquisition, 14.2% medical visits and 17.2% indirect costs). Patients taking pregabalin have a lower acquisition cost of drugs. CONCLUSIONS: Pregabalin is a favorable alternative for the treatment of NeP compared to duloxetine by saving US $567.1 per patient/year compared to duloxetine. Colombian stakeholders should consider these findings for future decision-making processes. 
PSY24 THE ECONOMIC IMPACT OF INCREASED USE OF MULTI-MODAL ANALGESIA FOR THE MANAGEMENT OF POST-SURGICAL PAIN IN THE HOSPITAL SETTING
OBJECTIVES:
Treating post-surgical patients with opioid and non-opioid medications simultaneously can be an effective way to treat pain, minimize opioid-associated side-effects, and reduce hospital length of stay (LOS). The objective of this exercise was to develop a budget impact model to evaluate the economic impact of increased use of multi-modal analgesia following orthopedic or abdominal/pelvic surgery in the hospital setting. METHODS: A total of 50,648 unique patient encounters from a 2009-2012 US electronic health record database were evaluated. Patients were segmented into 280 cohorts based on surgical procedure (40 unique orthopedic and abdominal/pelvic procedures) and NSAID risk factors (7 unique risk groups). Median LOS was calculated for each cohort and compared based on analgesia received (opioid-only vs. multi-modal). Findings were adjusted to fit the general case of a 250-bed hospital with an 80% occupancy rate and performing 3,400 total orthopedic and abdominal/pelvic surgeries/year. Median per-day hospital stay costs of $400 and $460 per orthopedic and abdominal/pelvic procedure, respectively, were applied. RESULTS: Current proportions of patients receiving multi-modal, opioid-only, and non-opioid-only therapy were 29.9%, 63.0%, and 7.1%, respectively. Multimodal therapy was associated with reduced LOS for 45.2% of cohorts, no change in LOS for 41.7% of cohorts, and increased LOS for 13.1% of cohorts. Increasing the proportion of patients receiving multi-modal therapy resulted in cost savings. Shifting 20% of patients from opioid-only to multi-modal therapy resulted in estimated annual savings of $71,526, while shifting 40% of patients in this manner reduced costs by $141,317. Conversely, shifting all patients treated with multi-modal therapy to opioid-only therapy increased annual costs by $105,204. CONCLUSIONS: The model supports the hypothesis that multi-modal therapy is associated with reduced LOS and reduced health care costs. While currently-available NSAIDs may present their own side-effect risks, NSAIDs with improved safety may further reduce costs, assuming similar efficacy and LOS effects. OBJECTIVES: Hemophilia A is a rare, genetic disorder occurring in males and its treatment involves infusing clotting factor concentrate (FVIII). Currently, the most widely-used FVIII product in China is plasma-derived FVIII. Since plasmaderived FVIII is sourced from local blood donations, it is associated with an increased risk of blood-borne infection. Blood-borne infections can be lifethreatening and have a significant cost on society. The objective of this study was to estimate the extra economic burden associated with a potential bloodborne infection in the hemophilia population of China. METHODS: An outbreak of hepatitis C virus (HCV) was used as a real life example of pathogen transmission in the Chinese hemophilia population. Decision tree analysis was adopted to calculate the expected life-time incremental cost associated with treating hemophilia patients infected with HCV. Costs were discounted and sensitivity analyses were conducted to test model sensitivity and assumptions. RESULTS: Preventing HCV in hemophilia patients is estimated to save an approximately 7 years of life per patient. Expected life-time additional treatment cost (FVIII cost not included) of a hemophilia patient infected with HCV was estimated at 855,341 RMB. Assuming 10% of the registered Chinese hemophilia A patients were affected by HCV, preventing HCV infection in these patients would have saved an estimated 774 million RMB in total. CONCLUSIONS: This research demonstrates the significant potential economic burden of treating hemophilia patients infected with a blood-borne pathogen such as HCV, as well as the value of utilizing a FVIII product that eliminates the transmission risk of another infectious disease similar to the burden associated with HCV.
PSY25 THE ECONOMIC BURDEN OF PATHOGEN TRANSMISSION WITHIN THE HEMOPHILIA POPULATION OF CHINA
PSY26 COSTS ASSOCIATED WITH BREAKTHROUGH PAIN IN CANCER PATIENTS: FINDINGS FROM THE NATIONAL BREAKTHROUGH PAIN SURVEY
